Profile picture

Professor Paolo Calabro

Hospital Sant'anna E San Sebastiano, Caserta (Italy)
Follow
Logo ESC

Contributor content

Withdrawing heart failure therapy after AF rhythm control: promise, caution, and perspective
Journal
Withdrawing heart failure therapy after AF rhythm control: promise, caution, and perspective
20 January 2026
Read more
Early DAPT discontinuation after acute myocardial infarction: finding the optimal TARGET
Journal
Early DAPT discontinuation after acute myocardial infarction: finding the optimal TARGET
30 September 2025
Read more
When more is worse: aspirin backfires in anticoagulated post-PCI patients
Journal
When more is worse: aspirin backfires in anticoagulated post-PCI patients
22 September 2025
Read more
An old drug in a new era: digitoxin in the spotlight after DIGIT-HF
Journal
An old drug in a new era: digitoxin in the spotlight after DIGIT-HF
12 September 2025
Read more
Artificial intelligence in cardiovascular pharmacotherapy: applications and perspectives
Journal
Artificial intelligence in cardiovascular pharmacotherapy: applications and perspectives
15 July 2025
Read more
Long-term antiplatelet monotherapy after PCI: searching for the smart choice
Journal
Long-term antiplatelet monotherapy after PCI: searching for the smart choice
26 April 2025
Read more
AZALEA–TIMI 71 trial: less bleeding with abelacimab compared to rivaroxaban in atrial fibrillation, but stroke prevention is uncertain
Journal
AZALEA–TIMI 71 trial: less bleeding with abelacimab compared to rivaroxaban in atrial fibrillation, but stroke prevention is uncertain
10 March 2025
Read more
OCEANIC-AF trial: factor XI inhibitors revolution in atrial fibrillation is on hold
Journal
OCEANIC-AF trial: factor XI inhibitors revolution in atrial fibrillation is on hold
10 September 2024
Read more
Sudden cardiac death after early-onset myocardial infarction: a multicentre longitudinal cohort study with a 20-year follow-up
Journal
Sudden cardiac death after early-onset myocardial infarction: a multicentre longitudinal cohort study with a 20-year follow-up
6 August 2024
Read more
Strike early–strike strong lipid-lowering strategy with proprotein convertase subtilisin/kexin type 9 inhibitors in acute coronary syndrome patients: real-world evidence from the AT-TARGET-IT registry
Journal
Strike early–strike strong lipid-lowering strategy with proprotein convertase subtilisin/kexin type 9 inhibitors in acute coronary syndrome patients: real-world evidence from the AT-TARGET-IT registry
24 May 2024
Read more

ESC 365 is supported by

novartis Explore sponsored resources